Health News

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.

Read more

Filed under: Pharmacy News
Tags: cancer, Eye Disease, Pharmacy

Related posts

• ThromboGenics’ Microplasmin Phase III Program Progressing According To Schedule (0)
  ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its lead product microplasmin, which is in Phase III trials for the treatment of vitreomacular adhesion, is progressing according to schedule. All protocol-specified, interim masked analyses by the independent [...]
  
  
• ThromboGenics Presents Positive Pooled Results From The MIVI-TRUST Phase III Program (0)
  ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France... Read more [tags] Pharmacy News [...]
  
  
• ThromboGenics Positive Microplasmin Phase II Data Published In Ophthalmology (0)
  ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Aca... Read more [tags] Pharmacy News [...]
  
  
• ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint (0)
  ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010. Read more [tags] Pharmacy News [...]
  
  
• ThromboGenics issues business update for the third-quarter of 2009 (0)
  ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009. Read more [tags] Pharmacy News [/tags]